Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, No. 16-2707 (Fed. Cir. Apr. 13, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

West-Ward Pharmaceuticals International Limited and West -Ward Pharmaceuticals Corp. (collectively, “West-Ward”) appeal from the decision of the United States District Court for the District of Delaware holding, after a bench trial, claims 1–9, 11–13, and 16 (“the assert- ed claims”) of U.S. Patent 8,586,610 (“the ’ 610 patent”) infringed and not in valid. See Vanda Pharm. Inc. v. Roxane Labs., Inc. , 203 F. Supp. 3d 412 (D. Del. 2016) (“Opinion”). For the following reasons, we affirm. BACKGROUND I.